Trials / Terminated
TerminatedNCT05489679
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Accutar Biotechnology Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: 1. To evaluate the safety and tolerability of AC682 2. To evaluate the pharmacokinetic of AC682 3. To evaluate the preliminary anti-tumor activity of AC682
Detailed description
This is a Phase I, open-label dose-escalation study of AC682, an orally available estrogen receptor degrader, given as a single agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC682 | Participants will receive AC682 by mouth daily in 28-day cycles. |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2023-09-28
- Completion
- 2023-09-28
- First posted
- 2022-08-05
- Last updated
- 2024-01-25
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05489679. Inclusion in this directory is not an endorsement.